PET/CT scan test to guide care in metastatic breast cancer
Part of Cancer clinical trials.
This trial studies whether a specific PET/CT scan using Ga-68 IAC helps diagnose and guide treatment decisions in people with metastatic breast cancer. It also focuses on whether the scan is safe and helpful for clinical management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old and can sign informed consent
- You have metastatic breast cancer (or another solid tumor meeting specific lab/genetic criteria)
- You can have the Ga-68 IAC PET/CT scan, and your first scan result shows positivity (SUV > 10)
- You have enough blood counts and organ function (kidneys, liver, and blood cells meet study thresholds)
- Your heart pumping strength (LVEF) is at least 50% on an echo or MUGA scan
- You can safely undergo the scan (including lying still) and fit in the PET/CT scanner
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well your breast cancer is responding to neoadjuvant therapy (treatment given before surgery). The goal is to help doctors personalize your care by checking if the cancer is shrinking.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study uses a special PET/CT scan (called 68Ga-NYM096) to see if it can help find different types of cancer. The scan may help doctors get clearer pictures of where cancer is in your body.
This study tests a new PET scan tracer called [68Ga]Ga-PentixaFor to see if it can better detect breast cancer that has spread. You may benefit if you have triple negative breast cancer that has come back or spread, and you are looking for more precise imaging.
This study tests a new PET scan tracer to show where HER2-positive breast cancer cells may be in the body. It may help doctors better “map” HER2 activity, including in people with HER2-positive or HER2-negative cancer.
Hear when a new Angiogenic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.